Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Other Non-Current Assets (2016 - 2025)

Karyopharm Therapeutics' Other Non-Current Assets history spans 14 years, with the latest figure at $351000.0 for Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 3.85% year-over-year to $351000.0; the TTM value through Dec 2025 reached $351000.0, up 3.85%, while the annual FY2025 figure was $351000.0, 3.85% up from the prior year.
  • Other Non-Current Assets reached $351000.0 in Q4 2025 per KPTI's latest filing, down from $1.3 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $1.3 million in Q1 2025 to a low of $301000.0 in Q4 2023.
  • Average Other Non-Current Assets over 5 years is $623350.0, with a median of $632000.0 recorded in 2022.
  • Peak YoY movement for Other Non-Current Assets: tumbled 52.45% in 2023, then surged 338.82% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $637000.0 in 2021, then fell by 0.63% to $633000.0 in 2022, then plummeted by 52.45% to $301000.0 in 2023, then rose by 12.29% to $338000.0 in 2024, then grew by 3.85% to $351000.0 in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Other Non-Current Assets are $351000.0 (Q4 2025), $1.3 million (Q3 2025), and $1.3 million (Q2 2025).